Viking initiates Phase II trial of VK2809 to treat hypercholesterolemia and NAFLD

US-based clinical-stage biopharmaceutical company Viking Therapeutics has initiated its Phase II clinical trial of VK2809 to treat primary hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news